-
Cambodian PM's cousin says owned 30% of scam-linked firm
-
Hegseth's church brings its Christian nationalism to Washington
-
Afrobeats' Tiwa Savage nurtures Africa's future talent
-
Venice Biennale opens in turmoil over Russian presence
-
Philips profits double in first quarter
-
Strasbourg on verge of European final amid fan displeasure at owners BlueCo
-
Tradition, Trump and tennis: Five things about Pope Leo
-
100 years on Earth: Iconic naturalist Attenborough marks century
-
Bondi Beach mass shooting accused faces 19 extra charges
-
Ukraine reports strike as Kyiv's ceasefire due to begin
-
Australia says 13 citizens linked to alleged IS members returning from Syria
-
Thunder overpower Lakers, Pistons down Cavs
-
Boycott-hit 70th Eurovision celebrated under high security
-
Court case challenges New Zealand's 'magical thinking' climate plans
-
Iran war jolts China's well-oiled manufacturing hub
-
Oil sinks and stocks rally on peace hopes, Samsung tops $1 trillion
-
Infantino defends World Cup ticket prices
-
Pistons hold off Cavs to win series-opener
-
Rubio rising? Duel with Vance for 2028 heats up
-
Teen shooter kills two at Brazil school
-
US pauses Hormuz escorts in bid for deal, as threats continue
-
Judge orders German car-ramming suspect to psychiatric hospital
-
Fresh UAE attacks blamed on Iran draw new reality in the Gulf
-
Transoft Solutions Acquires CADaptor Solutions
-
Arsenal on cusp of history after reaching Champions League final
-
Trump says pausing Hormuz operation in push for Iran deal
-
Wembanyama accused of 'obvious' illegal blocking
-
Musk 'was going to hit me,' OpenAI executive says at trial
-
NFL star Diggs cleared of assaulting personal chef
-
Fans 'set the standards' at rocking Emirates: Arteta
-
Rubio warns against 'destabilizing' acts on Taiwan before Trump China visit
-
US declares Iran offensive over, warns force remains an option
-
Saka ends Arsenal's 20-year wait to reach Champions League final
-
Outgoing Costa Rica leader secures top post in new cabinet
-
Rubio plays down Trump attacks on pope before Vatican trip
-
LIV Golf boss sees hope for new sponsors beyond 2026
-
Mexican BTS fans go wild as concerts grow near
-
Europe's first commercial robotaxi service rolls out in Croatia
-
Russian strikes kill 21 in Ukraine
-
Suspected hantavirus cases to be evacuated from cruise ship
-
G7 trade ministers meet, not expected to discuss US tariff threat
-
Hollywood star Malkovich gets Croatian citizenship
-
Mickelson pulls out of PGA Championship for family issues
-
Wales rugby great Halfpenny to retire
-
Rahm says player concessions needed to save LIV Golf
-
Bowlers, Samson keep Chennai afloat in IPL playoff race
-
Rolling Stones announce July 10 release of new album 'Foreign Tongues'
-
France's Macron taps ex-aide to head central bank
-
PSG 'not here to defend' against Bayern, says Luis Enrique
-
Trump says he works out 'one minute a day' as he restores fitness award
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
E.Raimundo--PC